REVIVE Logo REVIVE Logo REVIVE Logo
GARDP Forums Retina Logo
  • About
  • Experts
  • Webinars & Conferences
    • Webinars
    • Conference recordings
    • External Webinars
  • Antimicrobial Viewpoints
  • Resources
    • Library
    • Antimicrobial Encyclopaedia
    • Conference calendar
  • JOIN US
    • Log in
    • Lost your password?
    • Create your account
  • My account
    • Logout
You are here:Home-Antimicrobial Viewpoints

Find a Viewpoint

<br>Causes of antibiotic shortages and the solutions to address them</br><em> – by Enrico Baraldi</em>

Causes of antibiotic shortages and the solutions to address them – by Enrico Baraldi

10 February 2021
<br>Monitoring antimicrobial resistance in Ghana: a focus on the hospital environment</br><em> – by Abiola Isawumi and Lydia Mosi</em>

Monitoring antimicrobial resistance in Ghana: a focus on the hospital environment – by Abiola Isawumi and Lydia Mosi

18 January 2021
<br>Learning from IPC strategies for COVID-19 to mitigate AMR in rural Nigerian communities</br><em> – by Rachael Osagie</em>

Learning from IPC strategies for COVID-19 to mitigate AMR in rural Nigerian communities – by Rachael Osagie

9 December 2020
<br>The antibiotic R&D landscape in Japan</br><em> – by Norio Ohmagari</em>

The antibiotic R&D landscape in Japan – by Norio Ohmagari

25 November 2020
<br>Tackling the drug-resistance pandemic – 2020 and beyond</br><em> – by Laura J.V. Piddock</em>

Tackling the drug-resistance pandemic – 2020 and beyond – by Laura J.V. Piddock

23 November 2020
<br>Why are new antibacterials failing as commercial products?</br><em> – by Patricia A. Bradford</em>

Why are new antibacterials failing as commercial products? – by Patricia A. Bradford

19 November 2020
<br>COVID-19: Coinfection, secondary bacterial infections and AMR in India</br><em> – by Venkatasubramanian Ramasubramanian</em>

COVID-19: Coinfection, secondary bacterial infections and AMR in India – by Venkatasubramanian Ramasubramanian

12 November 2020
<br>Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic</br><em> – by Markus Heep, Esther Bettiol, Tanyaporn Wansom and Hilary Johnstone </em>

Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic – by Markus Heep, Esther Bettiol, Tanyaporn Wansom ...

15 October 2020
<br>A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need</br><em> – by John Rex</em>

A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need ...

6 October 2020
<br>Why we need a new access model for antibiotics</br><em> – by Yann Ferrisse and Fernando Pascual Martinez</em>

Why we need a new access model for antibiotics – by Yann Ferrisse and Fernando Pascual Martinez

1 October 2020
<br>Moving from paper to action – The status of National AMR Action Plans in African countries</br><em> – by Mirfin Mpundu</em>

Moving from paper to action – The status of National AMR Action Plans in African countries – by Mirfin Mpundu

25 September 2020
<br>Knowledge sharing for antimicrobial research: AntibioticDB and SPARK and why researchers should use them</br><em> – by Jack Stone and Maria Laura Ciusa</em>

Knowledge sharing for antimicrobial research: AntibioticDB and SPARK and why researchers should use them – by Jack Stone and Maria Laura ...

5 August 2020
  • 1
  • 2
  • 3
  • Next »

Share

FacebookTwitterRedditLinkedInEmail

REVIVE

REVIVE is a space for everybody with an interest in antimicrobial R&D.

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. We were created to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. We aim to develop five new treatments by 2025 to fight drug-resistant infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children.

Content

  • Antimicrobial Viewpoints (35)
  • Conferences recordings (18)
  • Experts (102)
  • External webinars (19)
  • Uncategorized (2)
  • Webinars (38)

Search site

CONNECT

  • Twitter
  • LinkedIn
  • YouTube

  • GARDP
  • DNDi
© All Rights Reserved
Privacy Policy | Terms of Use | Acceptable Use Policy | Cookie Policy
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our cookie policy